Hypercholesterolemia
Conditions
Keywords
Hypercholesterolemia with nondiabetic metabolic syndrome
Brief summary
The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg in the percentage reduction of LDL-C in Subjects with metabolic syndrome after 6 weeks of treatment.
Interventions
DRUGRosuvastatin
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Metabolic syndrome patient; Presence of 3 or more of the following: * Abdominal obesity (waist circumference): men \> 90cm(36 inch), women \> 80cm(32 inch) * Triglycerides ≥ 150 mg/dL (1.70 mmol/L) * HDL-C: men \< 40 mg/dL (1.04 mmol/L), women \< 50 mg/dL (1.3 mmol/L) * BP ≥130/≥85 mmHg or subject receiving anti-hypertensive treatment * Fasting blood glucose 110 mg dL (6.11 mmol/L) - 125 mg/dL (6.94 mmol.L) * Elevated LDL-C concentrations reported within 4 weeks of visit 1 as follows; * ≥ 130 mg/dL (3.36 mmol/L) to \< 220 mg/dL (5.69 mmol/L) in statin naive subjects (subjects who have not taken any lipid-lowering therapy known to affect LDL-C in the 4 weeks prior to visit 1) * ≥ 100 mg/dL (2.59 mmol/L) to \< 160 mg/dL (4.14 mmol/L) in subjects who have taken a lipid lowering drug(s) within 4 weeks of visit 1 * Triglyceride levels \< 400 mg/dL (4.52 mmol/L) * Women of childbearing potential should be using a medically acceptable form of chemical or mechanical contraception.
Exclusion criteria
* History of known diabetes mellitus * Use of anti-hyperglycaemic medication. * History of serious or hypersensitivity reactions to HMG-CoA reductase inhibitors, in particular history of myopathy. * No CHD or CHD Risk Equivalents and 0-1 Risk factors and Framingham 10-Year risk is \<10%. * History of heterozygous or homozygous familial hypercholesterolaemia or known type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia). * Active arterial disease such as unstable angina pectoris, myocardial infarction, transient ischaemic attack (TIA), cerebrovascular accident (CVA), coronary artery bypass surgery (CABG) or angioplasty within 2 months prior to entry in the dietary lead in period * Uncontrolled hypothyroidism defined as thyroid stimulating hormone (TSH) \> 1.5 times the upper limit of normal (ULN) at Visit 2 or subjects whose thyroid replacement therapy was initiated within 3 months of entry into dietary lead-in phase. * Current active liver disease (alanine aminotransferase \[ALT\] \> 2 x ULN) or severe hepatic impairment. * Unexplained serum CK \>3 times ULN (e.g. not due to recent trauma, intramuscular injections, heavy exercise, etc). * Serum creatinine \> 176 umol/L (2.0 mg/dL) * History of alcohol, or drug, abuse or both.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg in the percentage reduction of LDL-C in Subjects with metabolic syndrome after 6 weeks of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Bringing subjects to their established NCEP ATP III target goals for LDL-C | — |
| Bringing subjects to their non-HDL target goal(based on NCEP-ATP III criteria) | — |
| Modifying other lipids and lipid ratios | — |
| The secondary objectives of this study are to compare the effects of rosuvastatin 10mg with atorvastatin 10mg in subjects with metabolic syndrome, after 6weeks of treatment, on: | — |
| Glucose and insulin resistance | — |
| Safety | — |
| Modifying inflammatory markers | — |
Countries
South Korea
Outcome results
None listed